An observational study in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Bristol-Myers Squibb · Observational
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
347 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 110 are open to participants now.
This study's planned enrollment of 150 is below the median of 259 across 168 observational studies indexed under Cardiomyopathy, Hypertrophic.
Browse Cardiomyopathy, Hypertrophic studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will comprise of adult individuals diagnosed with Obstructive hypertrophic cardiomyopathy (oHCM) that have been prescribed mavacamten treatment between April 29th, 2022, and August 6th, 2024
Exclusion Criteria:
Drug: Mavacamten
According to the product label
New York Heart Association (NYHA) functional class
Time frame: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, and in increments of 12 weeks thereafter from index
Left ventricular outflow tract (LVOT) gradient and associated parameters
Time frame: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, and in increments of 12 weeks thereafter from index
Left ventricular ejection fraction (LVEF) and associated parameters
Time frame: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, and in increments of 12 weeks thereafter from index
Mavacamten dose at initiation
Time frame: Day 1
Mavacamten dose change
Time frame: Up to 72 weeks
Reason for mavacamten dose change
Time frame: Up to 72 weeks
Reason for mavacamten permanent discontinuation
Time frame: Up to 72 weeks
Reason for treatment interruption
Time frame: Up to 72 weeks
Prior Obstructive hypertrophic cardiomyopathy (oHCM) therapies
Time frame: Baseline
Concurrent Obstructive hypertrophic cardiomyopathy (oHCM) therapies
Time frame: Up to 72 weeks
Other cardiovascular-related treatments prescribed
Time frame: Up to 72 weeks
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb